Merck, Hanmi sign $870M deal for NASH drug August 4, 2020 Auto Bot BioPharma, biopharma nl, Merck & Co, NASH, nonalcoholic steatohepatitis, South Korea 0 Hanmi will retain options for the drug, efinopegdutide, in Korea under the deal, in which Merck is paying the Seoul-based company $10 million upfront and up to $860 for development, regulatory and commercialization milestones.